Bahrain vs Europe (WHO region): Pneumococcal conjugate second or third-dose vaccines (PCVc)
Bahrain
99.0%
in 2025
Europe (WHO region)
83.0%
in 2025
Bahrain rank
1st
Europe (WHO region) rank
3rd
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Bahrain
- Europe (WHO region)
How they compare
Bahrain currently reports 99.0% against 83.0% in Europe (WHO region), a difference of 16.0%.
That makes Bahrain's figure about 1.2 times Europe (WHO region)'s.
Across all 18 years both countries report, Bahrain has been ahead every year.
Bahrain ranks 1st and Europe (WHO region) ranks 3rd of 194 countries.
Bahrain has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Bahrain | Europe (WHO region) | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 55.0% | 15.5% | 39.5% | Bahrain |
| 2010s | 98.3% | 54.4% | 43.9% | Bahrain |
| 2020s | 98.8% | 81.8% | 17.0% | Bahrain |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Bahrain or Europe (WHO region)?
- Bahrain, at 99.0% against 83.0% in Europe (WHO region) as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Bahrain and Europe (WHO region)?
- 16.0%, with Bahrain ahead.
- How many years of comparable data are there for Bahrain and Europe (WHO region)?
- 18 years are reported by both, from 2008 to 2025.
- How do Bahrain and Europe (WHO region) rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Bahrain ranks 1st and Europe (WHO region) ranks 3rd of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.